Marian Rewers
Concepts (927)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 391 | 2026 | 3847 | 20.690 |
Why?
| | Autoimmunity | 135 | 2026 | 926 | 12.020 |
Why?
| | Islets of Langerhans | 122 | 2026 | 834 | 11.620 |
Why?
| | Autoantibodies | 189 | 2026 | 1497 | 11.300 |
Why?
| | Celiac Disease | 54 | 2026 | 308 | 7.110 |
Why?
| | Genetic Predisposition to Disease | 97 | 2026 | 2413 | 4.380 |
Why?
| | Coronary Artery Disease | 34 | 2018 | 726 | 3.260 |
Why?
| | Diabetic Angiopathies | 28 | 2017 | 251 | 3.080 |
Why?
| | Child, Preschool | 210 | 2026 | 11656 | 2.980 |
Why?
| | HLA-DQ Antigens | 38 | 2025 | 173 | 2.950 |
Why?
| | Child | 243 | 2026 | 22493 | 2.820 |
Why?
| | Calcinosis | 23 | 2015 | 235 | 2.780 |
Why?
| | HLA-DR Antigens | 28 | 2021 | 219 | 2.650 |
Why?
| | Insulin Resistance | 55 | 2018 | 1255 | 2.520 |
Why?
| | Insulin | 76 | 2026 | 2506 | 2.470 |
Why?
| | Disease Progression | 83 | 2026 | 2874 | 2.390 |
Why?
| | Infant | 169 | 2026 | 9911 | 2.390 |
Why?
| | Risk Factors | 165 | 2026 | 10641 | 2.240 |
Why?
| | Humans | 513 | 2026 | 144228 | 2.120 |
Why?
| | Diabetic Ketoacidosis | 16 | 2026 | 210 | 2.120 |
Why?
| | Transglutaminases | 30 | 2026 | 159 | 2.030 |
Why?
| | Polymorphism, Single Nucleotide | 39 | 2026 | 2178 | 2.010 |
Why?
| | Blood Glucose | 38 | 2022 | 2325 | 2.000 |
Why?
| | Genotype | 63 | 2026 | 1839 | 1.970 |
Why?
| | Autoimmune Diseases | 17 | 2026 | 464 | 1.960 |
Why?
| | Male | 348 | 2026 | 71757 | 1.900 |
Why?
| | Prospective Studies | 101 | 2026 | 7911 | 1.890 |
Why?
| | Biomarkers | 50 | 2026 | 4258 | 1.870 |
Why?
| | Insulin Antibodies | 24 | 2026 | 103 | 1.850 |
Why?
| | Adolescent | 149 | 2026 | 22282 | 1.850 |
Why?
| | Female | 356 | 2026 | 77795 | 1.840 |
Why?
| | Mass Screening | 23 | 2026 | 1329 | 1.690 |
Why?
| | Glutamate Decarboxylase | 35 | 2025 | 165 | 1.640 |
Why?
| | Hyperglycemia | 11 | 2026 | 370 | 1.590 |
Why?
| | Diabetic Nephropathies | 19 | 2020 | 310 | 1.580 |
Why?
| | Insulin-Secreting Cells | 15 | 2023 | 391 | 1.470 |
Why?
| | Coronary Disease | 15 | 2010 | 369 | 1.430 |
Why?
| | Prediabetic State | 14 | 2023 | 257 | 1.390 |
Why?
| | Diet | 30 | 2026 | 1270 | 1.370 |
Why?
| | Case-Control Studies | 59 | 2026 | 3618 | 1.350 |
Why?
| | Follow-Up Studies | 65 | 2026 | 5327 | 1.240 |
Why?
| | HLA Antigens | 24 | 2025 | 227 | 1.200 |
Why?
| | Health Care Costs | 2 | 2025 | 418 | 1.190 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 10 | 2022 | 48 | 1.180 |
Why?
| | Glutens | 11 | 2023 | 59 | 1.150 |
Why?
| | Cohort Studies | 68 | 2026 | 5876 | 1.130 |
Why?
| | Diabetes Mellitus, Type 2 | 36 | 2025 | 2590 | 1.110 |
Why?
| | Fatty Acids, Omega-3 | 8 | 2020 | 142 | 1.090 |
Why?
| | Enterovirus Infections | 6 | 2023 | 174 | 1.050 |
Why?
| | HLA-DR3 Antigen | 17 | 2025 | 76 | 1.030 |
Why?
| | Polymorphism, Genetic | 15 | 2019 | 618 | 1.020 |
Why?
| | Adult | 160 | 2026 | 40230 | 1.020 |
Why?
| | Environment | 5 | 2018 | 306 | 1.000 |
Why?
| | DNA Methylation | 8 | 2026 | 676 | 0.990 |
Why?
| | Infant, Newborn | 66 | 2025 | 6380 | 0.960 |
Why?
| | H(+)-K(+)-Exchanging ATPase | 2 | 2017 | 8 | 0.950 |
Why?
| | Erythrocyte Membrane | 5 | 2015 | 55 | 0.940 |
Why?
| | Atherosclerosis | 15 | 2018 | 401 | 0.900 |
Why?
| | HLA-DR4 Antigen | 17 | 2025 | 75 | 0.890 |
Why?
| | Longitudinal Studies | 31 | 2026 | 2955 | 0.870 |
Why?
| | Colorado | 44 | 2024 | 4591 | 0.860 |
Why?
| | Age of Onset | 20 | 2026 | 543 | 0.850 |
Why?
| | Middle Aged | 137 | 2025 | 35731 | 0.850 |
Why?
| | Diabetes Complications | 7 | 2019 | 227 | 0.820 |
Why?
| | Coronary Vessels | 8 | 2017 | 250 | 0.820 |
Why?
| | Incidence | 36 | 2022 | 2852 | 0.820 |
Why?
| | Albuminuria | 12 | 2016 | 187 | 0.820 |
Why?
| | Enterovirus | 5 | 2019 | 83 | 0.810 |
Why?
| | Seroconversion | 7 | 2026 | 50 | 0.790 |
Why?
| | Vitamin D | 8 | 2026 | 402 | 0.780 |
Why?
| | Proportional Hazards Models | 26 | 2024 | 1306 | 0.780 |
Why?
| | Vascular Calcification | 9 | 2018 | 111 | 0.770 |
Why?
| | Predictive Value of Tests | 25 | 2019 | 2097 | 0.730 |
Why?
| | Young Adult | 53 | 2026 | 13949 | 0.710 |
Why?
| | Glucose Tolerance Test | 26 | 2022 | 376 | 0.690 |
Why?
| | C-Peptide | 7 | 2025 | 188 | 0.680 |
Why?
| | Breast Feeding | 18 | 2021 | 447 | 0.670 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 12 | 2025 | 54 | 0.670 |
Why?
| | Genetic Testing | 8 | 2019 | 478 | 0.660 |
Why?
| | Inflammation | 10 | 2026 | 2900 | 0.660 |
Why?
| | Haplotypes | 15 | 2026 | 491 | 0.660 |
Why?
| | Fatty Acids | 6 | 2021 | 450 | 0.650 |
Why?
| | Calcium | 8 | 2023 | 1183 | 0.640 |
Why?
| | Zinc Transporter 8 | 8 | 2025 | 70 | 0.630 |
Why?
| | Blood Glucose Self-Monitoring | 6 | 2022 | 706 | 0.630 |
Why?
| | Antibodies, Viral | 6 | 2023 | 686 | 0.610 |
Why?
| | Autoantigens | 9 | 2025 | 432 | 0.600 |
Why?
| | GTP-Binding Proteins | 8 | 2026 | 154 | 0.600 |
Why?
| | Early Diagnosis | 7 | 2025 | 247 | 0.560 |
Why?
| | Infant Nutritional Physiological Phenomena | 5 | 2021 | 149 | 0.560 |
Why?
| | Prevalence | 23 | 2024 | 2820 | 0.560 |
Why?
| | Uric Acid | 6 | 2018 | 166 | 0.560 |
Why?
| | Cross-Sectional Studies | 36 | 2025 | 5776 | 0.540 |
Why?
| | Body Mass Index | 23 | 2025 | 2446 | 0.530 |
Why?
| | Germany | 12 | 2024 | 141 | 0.520 |
Why?
| | Logistic Models | 24 | 2017 | 2096 | 0.520 |
Why?
| | Infant Food | 7 | 2018 | 64 | 0.520 |
Why?
| | Smoking | 9 | 2025 | 1557 | 0.510 |
Why?
| | Adiponectin | 5 | 2016 | 247 | 0.510 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2016 | 97 | 0.510 |
Why?
| | Sensitivity and Specificity | 22 | 2026 | 1986 | 0.500 |
Why?
| | Edible Grain | 4 | 2008 | 49 | 0.500 |
Why?
| | Finland | 16 | 2025 | 81 | 0.500 |
Why?
| | Fibrinogen | 5 | 2019 | 180 | 0.500 |
Why?
| | Glomerular Filtration Rate | 15 | 2020 | 751 | 0.490 |
Why?
| | Monitoring, Physiologic | 2 | 2009 | 291 | 0.490 |
Why?
| | Age Factors | 38 | 2026 | 3295 | 0.480 |
Why?
| | Metabolomics | 5 | 2021 | 731 | 0.480 |
Why?
| | Arteriosclerosis | 17 | 2004 | 83 | 0.480 |
Why?
| | Prognosis | 20 | 2026 | 4221 | 0.470 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2013 | 439 | 0.470 |
Why?
| | Genome-Wide Association Study | 10 | 2026 | 1455 | 0.460 |
Why?
| | Hypoglycemia | 5 | 2014 | 473 | 0.460 |
Why?
| | Lipids | 5 | 2019 | 701 | 0.450 |
Why?
| | Triglycerides | 13 | 2020 | 517 | 0.450 |
Why?
| | Hypertension | 11 | 2021 | 1241 | 0.450 |
Why?
| | Milk | 7 | 2017 | 118 | 0.450 |
Why?
| | Luminescent Measurements | 4 | 2021 | 76 | 0.440 |
Why?
| | Environmental Exposure | 4 | 2025 | 586 | 0.440 |
Why?
| | Prenatal Exposure Delayed Effects | 7 | 2025 | 673 | 0.440 |
Why?
| | Probiotics | 3 | 2022 | 61 | 0.430 |
Why?
| | C-Reactive Protein | 5 | 2018 | 419 | 0.430 |
Why?
| | Helicobacter Infections | 1 | 2014 | 30 | 0.430 |
Why?
| | Helicobacter pylori | 1 | 2014 | 45 | 0.420 |
Why?
| | Risk | 17 | 2020 | 902 | 0.420 |
Why?
| | Respiratory Tract Infections | 5 | 2025 | 395 | 0.420 |
Why?
| | Antibodies | 5 | 2024 | 402 | 0.410 |
Why?
| | Micronutrients | 3 | 2026 | 95 | 0.410 |
Why?
| | Time Factors | 21 | 2018 | 7081 | 0.410 |
Why?
| | Dietary Supplements | 7 | 2024 | 577 | 0.400 |
Why?
| | Asymptomatic Diseases | 3 | 2023 | 98 | 0.400 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2014 | 54 | 0.400 |
Why?
| | Inflammation Mediators | 3 | 2026 | 511 | 0.400 |
Why?
| | Fatty Acid Desaturases | 1 | 2013 | 31 | 0.400 |
Why?
| | Sweden | 13 | 2024 | 112 | 0.400 |
Why?
| | Dyslipidemias | 4 | 2015 | 170 | 0.400 |
Why?
| | Immunogenetics | 1 | 2013 | 7 | 0.400 |
Why?
| | Alleles | 14 | 2021 | 883 | 0.390 |
Why?
| | Risk Assessment | 17 | 2021 | 3560 | 0.390 |
Why?
| | Glucose Clamp Technique | 8 | 2020 | 200 | 0.390 |
Why?
| | Proteomics | 6 | 2025 | 1194 | 0.380 |
Why?
| | United States | 35 | 2025 | 15641 | 0.380 |
Why?
| | HLA-D Antigens | 5 | 2019 | 30 | 0.380 |
Why?
| | Bacteriophages | 2 | 2025 | 111 | 0.370 |
Why?
| | Child Nutritional Physiological Phenomena | 4 | 2019 | 104 | 0.370 |
Why?
| | Dietary Fats | 3 | 2014 | 315 | 0.370 |
Why?
| | Oxylipins | 3 | 2023 | 47 | 0.370 |
Why?
| | Cost-Benefit Analysis | 4 | 2026 | 619 | 0.370 |
Why?
| | Fasting | 12 | 2015 | 282 | 0.360 |
Why?
| | Genetic Variation | 4 | 2026 | 990 | 0.360 |
Why?
| | Epitopes | 6 | 2025 | 491 | 0.360 |
Why?
| | Vitamin D Deficiency | 2 | 2011 | 187 | 0.360 |
Why?
| | Lipoproteins | 4 | 2015 | 163 | 0.360 |
Why?
| | Apolipoproteins A | 2 | 2006 | 17 | 0.350 |
Why?
| | Ascorbic Acid | 4 | 2023 | 181 | 0.350 |
Why?
| | Addison Disease | 6 | 2012 | 39 | 0.340 |
Why?
| | Major Histocompatibility Complex | 6 | 2026 | 229 | 0.340 |
Why?
| | Liver | 3 | 2012 | 1848 | 0.340 |
Why?
| | Adipocytes | 1 | 2012 | 221 | 0.330 |
Why?
| | Fetal Blood | 6 | 2021 | 340 | 0.330 |
Why?
| | Sex Factors | 20 | 2020 | 2081 | 0.330 |
Why?
| | Life Style | 5 | 2015 | 485 | 0.330 |
Why?
| | Hypolipidemic Agents | 2 | 2010 | 86 | 0.330 |
Why?
| | Dietary Proteins | 4 | 2019 | 136 | 0.330 |
Why?
| | Hypoglycemic Agents | 8 | 2020 | 1393 | 0.320 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 711 | 0.320 |
Why?
| | Cholesterol, HDL | 8 | 2015 | 194 | 0.320 |
Why?
| | Plant Proteins | 1 | 2011 | 112 | 0.320 |
Why?
| | Epidemics | 1 | 2011 | 98 | 0.310 |
Why?
| | Precision Medicine | 1 | 2014 | 457 | 0.310 |
Why?
| | Research | 2 | 2013 | 427 | 0.310 |
Why?
| | Eating | 5 | 2023 | 389 | 0.310 |
Why?
| | Surveys and Questionnaires | 17 | 2024 | 6031 | 0.310 |
Why?
| | Blood Proteins | 3 | 2017 | 250 | 0.300 |
Why?
| | Patient Education as Topic | 2 | 2005 | 794 | 0.300 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 27 | 0.300 |
Why?
| | HLA-DQ beta-Chains | 12 | 2019 | 59 | 0.300 |
Why?
| | Cesarean Section | 2 | 2024 | 224 | 0.300 |
Why?
| | CTLA-4 Antigen | 5 | 2017 | 107 | 0.300 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2025 | 1138 | 0.300 |
Why?
| | Cystatin C | 6 | 2014 | 65 | 0.300 |
Why?
| | Obesity | 12 | 2015 | 3087 | 0.300 |
Why?
| | Family Health | 8 | 2017 | 193 | 0.300 |
Why?
| | Multivariate Analysis | 10 | 2016 | 1509 | 0.290 |
Why?
| | Cytokines | 6 | 2026 | 2098 | 0.290 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1048 | 0.290 |
Why?
| | Sex Distribution | 6 | 2011 | 380 | 0.290 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 38 | 0.290 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 753 | 0.290 |
Why?
| | Rotavirus | 2 | 2016 | 20 | 0.280 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.280 |
Why?
| | Antigens, CD | 2 | 2009 | 564 | 0.280 |
Why?
| | Feces | 7 | 2025 | 509 | 0.280 |
Why?
| | Diabetes Mellitus | 8 | 2009 | 1088 | 0.270 |
Why?
| | Europe | 11 | 2021 | 411 | 0.270 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.270 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.270 |
Why?
| | Adiposity | 7 | 2020 | 537 | 0.270 |
Why?
| | Epigenesis, Genetic | 4 | 2026 | 686 | 0.260 |
Why?
| | Reference Values | 10 | 2012 | 807 | 0.260 |
Why?
| | Seroepidemiologic Studies | 4 | 2023 | 174 | 0.260 |
Why?
| | Pregnancy | 18 | 2025 | 7180 | 0.260 |
Why?
| | Tomography, X-Ray Computed | 12 | 2018 | 2788 | 0.260 |
Why?
| | Gene-Environment Interaction | 5 | 2024 | 179 | 0.260 |
Why?
| | Diet, Gluten-Free | 3 | 2024 | 56 | 0.260 |
Why?
| | Glycopeptides | 2 | 2018 | 44 | 0.250 |
Why?
| | Proteome | 2 | 2025 | 511 | 0.250 |
Why?
| | Iron | 3 | 2023 | 356 | 0.250 |
Why?
| | Survival Analysis | 4 | 2021 | 1361 | 0.250 |
Why?
| | Adipose Tissue | 4 | 2018 | 657 | 0.250 |
Why?
| | HLA-DRB1 Chains | 8 | 2019 | 111 | 0.250 |
Why?
| | Metabolome | 2 | 2020 | 383 | 0.250 |
Why?
| | Rotavirus Infections | 1 | 2006 | 35 | 0.250 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.250 |
Why?
| | RNA, Viral | 3 | 2019 | 692 | 0.240 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2011 | 208 | 0.240 |
Why?
| | Patient Compliance | 3 | 2023 | 614 | 0.240 |
Why?
| | Exercise | 4 | 2023 | 2198 | 0.240 |
Why?
| | Apolipoproteins C | 1 | 2006 | 3 | 0.240 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 193 | 0.240 |
Why?
| | Remission Induction | 2 | 2004 | 309 | 0.240 |
Why?
| | HLA-DR alpha-Chains | 1 | 2026 | 5 | 0.240 |
Why?
| | Complement C4a | 1 | 2026 | 9 | 0.240 |
Why?
| | Overweight | 3 | 2021 | 608 | 0.240 |
Why?
| | Regression Analysis | 15 | 2014 | 1003 | 0.240 |
Why?
| | Infant Formula | 3 | 2019 | 71 | 0.240 |
Why?
| | Contraception | 1 | 2008 | 167 | 0.240 |
Why?
| | Cardiovascular Diseases | 8 | 2018 | 2101 | 0.230 |
Why?
| | Protein Tyrosine Phosphatases | 7 | 2006 | 167 | 0.230 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.230 |
Why?
| | Chromosome Mapping | 4 | 2025 | 511 | 0.230 |
Why?
| | Carotid Arteries | 5 | 1998 | 203 | 0.230 |
Why?
| | Quantitative Trait Loci | 2 | 2025 | 374 | 0.230 |
Why?
| | Hypersensitivity, Immediate | 1 | 2025 | 41 | 0.230 |
Why?
| | Gene Frequency | 10 | 2020 | 483 | 0.230 |
Why?
| | Maternal Age | 3 | 2004 | 127 | 0.230 |
Why?
| | Aged | 45 | 2021 | 25675 | 0.230 |
Why?
| | Diet Records | 4 | 2019 | 85 | 0.230 |
Why?
| | Proinsulin | 3 | 2014 | 52 | 0.220 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2025 | 15 | 0.220 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2011 | 366 | 0.220 |
Why?
| | Glucose Intolerance | 7 | 2013 | 145 | 0.220 |
Why?
| | Plasminogen Activator Inhibitor 1 | 6 | 2017 | 85 | 0.220 |
Why?
| | Tobacco Smoke Pollution | 4 | 2019 | 237 | 0.220 |
Why?
| | Apolipoproteins | 3 | 2014 | 37 | 0.220 |
Why?
| | Introns | 1 | 2026 | 252 | 0.220 |
Why?
| | Abdominal Wall | 1 | 2004 | 27 | 0.220 |
Why?
| | Mass Spectrometry | 4 | 2025 | 748 | 0.220 |
Why?
| | Linear Models | 7 | 2016 | 859 | 0.220 |
Why?
| | Docosahexaenoic Acids | 3 | 2021 | 87 | 0.220 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 500 | 0.210 |
Why?
| | Health Surveys | 3 | 2018 | 510 | 0.210 |
Why?
| | Immunotherapy | 1 | 2009 | 670 | 0.210 |
Why?
| | Hyperlipidemias | 1 | 2005 | 121 | 0.210 |
Why?
| | Immunoglobulin A | 6 | 2024 | 218 | 0.210 |
Why?
| | Bone Density | 2 | 2020 | 501 | 0.210 |
Why?
| | Fever | 1 | 2025 | 311 | 0.200 |
Why?
| | Delivery, Obstetric | 2 | 2004 | 161 | 0.200 |
Why?
| | Coronary Angiography | 2 | 2014 | 312 | 0.200 |
Why?
| | Vitamin B Complex | 1 | 2024 | 40 | 0.200 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 55 | 0.200 |
Why?
| | Animals | 26 | 2022 | 38231 | 0.200 |
Why?
| | Seasons | 5 | 2024 | 552 | 0.200 |
Why?
| | Alanine Transaminase | 2 | 2015 | 147 | 0.200 |
Why?
| | Peptide Library | 1 | 2024 | 95 | 0.200 |
Why?
| | Haptoglobins | 3 | 2013 | 66 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2026 | 858 | 0.200 |
Why?
| | Birth Weight | 4 | 2016 | 524 | 0.200 |
Why?
| | Iron Overload | 1 | 2023 | 19 | 0.200 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 382 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 162 | 0.190 |
Why?
| | Child Development | 2 | 2020 | 494 | 0.190 |
Why?
| | Virus Diseases | 4 | 2021 | 217 | 0.190 |
Why?
| | Muscle, Skeletal | 2 | 2018 | 1809 | 0.190 |
Why?
| | ROC Curve | 4 | 2019 | 608 | 0.190 |
Why?
| | Ketone Bodies | 2 | 2014 | 15 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 4 | 2018 | 958 | 0.180 |
Why?
| | Alcohol Drinking | 1 | 2009 | 831 | 0.180 |
Why?
| | Influenza, Human | 2 | 2022 | 614 | 0.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 419 | 0.180 |
Why?
| | Costs and Cost Analysis | 2 | 2020 | 215 | 0.180 |
Why?
| | Pediatrics | 4 | 2020 | 1093 | 0.180 |
Why?
| | Diabetic Retinopathy | 4 | 2016 | 206 | 0.180 |
Why?
| | Complement System Proteins | 1 | 2025 | 318 | 0.180 |
Why?
| | Lipid Metabolism | 2 | 2019 | 524 | 0.180 |
Why?
| | Mothers | 4 | 2021 | 774 | 0.180 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2021 | 181 | 0.180 |
Why?
| | Peptides | 3 | 2024 | 993 | 0.180 |
Why?
| | Blood Pressure | 9 | 2014 | 1752 | 0.180 |
Why?
| | Age Distribution | 5 | 2011 | 396 | 0.180 |
Why?
| | Parents | 6 | 2023 | 1415 | 0.180 |
Why?
| | Odds Ratio | 6 | 2015 | 1057 | 0.180 |
Why?
| | Lipase | 1 | 2002 | 72 | 0.170 |
Why?
| | Dietary Approaches To Stop Hypertension | 1 | 2021 | 13 | 0.170 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2021 | 48 | 0.170 |
Why?
| | Glycerol | 2 | 2012 | 89 | 0.170 |
Why?
| | Receptors, Calcitriol | 2 | 2012 | 55 | 0.170 |
Why?
| | T-Lymphocytes | 3 | 2025 | 2045 | 0.170 |
Why?
| | Monitoring, Ambulatory | 2 | 2014 | 91 | 0.170 |
Why?
| | Growth | 2 | 2016 | 51 | 0.170 |
Why?
| | Reproducibility of Results | 9 | 2021 | 3402 | 0.170 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1256 | 0.170 |
Why?
| | Body Height | 3 | 2014 | 202 | 0.170 |
Why?
| | White Matter | 1 | 2023 | 151 | 0.170 |
Why?
| | Polysaccharides | 2 | 2022 | 89 | 0.170 |
Why?
| | Gastroenteritis | 2 | 2016 | 62 | 0.170 |
Why?
| | Gestational Age | 3 | 2020 | 974 | 0.170 |
Why?
| | F2-Isoprostanes | 2 | 2015 | 21 | 0.170 |
Why?
| | Bacteria | 2 | 2025 | 892 | 0.160 |
Why?
| | Luminescence | 3 | 2016 | 39 | 0.160 |
Why?
| | Vitamins | 2 | 2020 | 177 | 0.160 |
Why?
| | HLA-B8 Antigen | 4 | 2012 | 11 | 0.160 |
Why?
| | Ketosis | 1 | 2020 | 12 | 0.160 |
Why?
| | Influenza Vaccines | 2 | 2017 | 527 | 0.160 |
Why?
| | Genomics | 2 | 2021 | 836 | 0.160 |
Why?
| | Disease Susceptibility | 6 | 2020 | 351 | 0.160 |
Why?
| | Dietary Carbohydrates | 2 | 2015 | 153 | 0.160 |
Why?
| | Dietary Sucrose | 1 | 2020 | 50 | 0.160 |
Why?
| | Neonatal Screening | 4 | 2020 | 175 | 0.160 |
Why?
| | Biopsy | 5 | 2017 | 1069 | 0.160 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.160 |
Why?
| | Sugars | 1 | 2020 | 41 | 0.160 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 21 | 0.160 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 115 | 0.150 |
Why?
| | Energy Intake | 5 | 2023 | 505 | 0.150 |
Why?
| | Life Change Events | 1 | 2021 | 146 | 0.150 |
Why?
| | Mice, Inbred NOD | 5 | 2015 | 618 | 0.150 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 84 | 0.150 |
Why?
| | Interferon-gamma | 2 | 2021 | 792 | 0.150 |
Why?
| | Phospholipids | 1 | 2021 | 211 | 0.150 |
Why?
| | Kidney | 2 | 2018 | 1487 | 0.150 |
Why?
| | Developing Countries | 2 | 1993 | 315 | 0.150 |
Why?
| | Metabolic Clearance Rate | 3 | 2014 | 116 | 0.150 |
Why?
| | Epidemiologic Methods | 4 | 2014 | 92 | 0.150 |
Why?
| | Oxidative Stress | 3 | 2017 | 1376 | 0.150 |
Why?
| | Apolipoproteins B | 2 | 2015 | 45 | 0.150 |
Why?
| | Cation Transport Proteins | 3 | 2011 | 118 | 0.150 |
Why?
| | Measles | 1 | 2019 | 46 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2003 | 423 | 0.150 |
Why?
| | Iodide Peroxidase | 5 | 2025 | 34 | 0.150 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 62 | 0.150 |
Why?
| | Glycosuria | 2 | 2009 | 10 | 0.150 |
Why?
| | Fatty Acids, Omega-6 | 4 | 2020 | 48 | 0.150 |
Why?
| | Butyrates | 1 | 2019 | 67 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2019 | 147 | 0.140 |
Why?
| | Cotinine | 1 | 2019 | 79 | 0.140 |
Why?
| | Genes, MHC Class II | 3 | 2012 | 77 | 0.140 |
Why?
| | Uromodulin | 1 | 2018 | 22 | 0.140 |
Why?
| | Genetic Markers | 4 | 2013 | 338 | 0.140 |
Why?
| | Cholesterol | 5 | 2014 | 398 | 0.140 |
Why?
| | Mexican Americans | 3 | 2014 | 114 | 0.140 |
Why?
| | Health Expenditures | 1 | 2020 | 190 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 265 | 0.140 |
Why?
| | HLA-DP beta-Chains | 3 | 2015 | 90 | 0.140 |
Why?
| | Self Report | 3 | 2020 | 867 | 0.140 |
Why?
| | Models, Biological | 5 | 2019 | 1836 | 0.140 |
Why?
| | Squalene | 1 | 2017 | 8 | 0.130 |
Why?
| | HLA-DR2 Antigen | 2 | 2012 | 7 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 46 | 0.130 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.130 |
Why?
| | Amino Acid Sequence | 6 | 2024 | 2149 | 0.130 |
Why?
| | Phenotype | 8 | 2024 | 3185 | 0.130 |
Why?
| | Immunization | 1 | 1999 | 375 | 0.130 |
Why?
| | Antipyretics | 1 | 2017 | 5 | 0.130 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 174 | 0.130 |
Why?
| | Feeding Behavior | 3 | 2013 | 684 | 0.130 |
Why?
| | Cost of Illness | 1 | 2020 | 320 | 0.130 |
Why?
| | Radioimmunoassay | 6 | 2016 | 167 | 0.130 |
Why?
| | Blood Cell Count | 1 | 2017 | 53 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2017 | 1826 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2019 | 383 | 0.130 |
Why?
| | Rheumatoid Factor | 3 | 2007 | 175 | 0.130 |
Why?
| | Immunologic Memory | 1 | 2019 | 376 | 0.130 |
Why?
| | Models, Genetic | 2 | 2017 | 535 | 0.130 |
Why?
| | Body Composition | 3 | 2020 | 715 | 0.130 |
Why?
| | Kidney Diseases | 2 | 2012 | 418 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 245 | 0.130 |
Why?
| | Genetic Loci | 3 | 2015 | 275 | 0.130 |
Why?
| | Rural Health | 2 | 2002 | 87 | 0.130 |
Why?
| | Poland | 4 | 2010 | 35 | 0.120 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 1 | 2017 | 59 | 0.120 |
Why?
| | Milk Proteins | 1 | 1996 | 35 | 0.120 |
Why?
| | Toxins, Biological | 1 | 2016 | 12 | 0.120 |
Why?
| | Homozygote | 5 | 2014 | 201 | 0.120 |
Why?
| | Arachidonic Acid | 2 | 2021 | 107 | 0.120 |
Why?
| | Models, Theoretical | 2 | 2017 | 586 | 0.120 |
Why?
| | Immunoglobulin G | 4 | 2021 | 899 | 0.120 |
Why?
| | Patient Care Planning | 2 | 2015 | 167 | 0.120 |
Why?
| | Body Weight | 3 | 2016 | 993 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2017 | 126 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1029 | 0.120 |
Why?
| | Hygiene | 1 | 2016 | 29 | 0.120 |
Why?
| | HLA-A1 Antigen | 2 | 2006 | 4 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 7 | 2006 | 44 | 0.120 |
Why?
| | HLA-DP Antigens | 2 | 2007 | 32 | 0.120 |
Why?
| | Diet Surveys | 4 | 2021 | 92 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 78 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2017 | 123 | 0.120 |
Why?
| | Polymerase Chain Reaction | 5 | 2011 | 1058 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1531 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Feeding Methods | 1 | 2015 | 5 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 766 | 0.110 |
Why?
| | Histocompatibility Testing | 6 | 2017 | 121 | 0.110 |
Why?
| | Complement C3 | 1 | 2016 | 190 | 0.110 |
Why?
| | Medical Records | 2 | 2007 | 183 | 0.110 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2018 | 647 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 277 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 559 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2021 | 1150 | 0.110 |
Why?
| | Genetic Association Studies | 4 | 2020 | 375 | 0.110 |
Why?
| | Carbohydrates | 1 | 2015 | 67 | 0.110 |
Why?
| | Dietary Fiber | 1 | 2015 | 58 | 0.110 |
Why?
| | Child Day Care Centers | 1 | 2015 | 44 | 0.110 |
Why?
| | Oxygen | 1 | 2020 | 1002 | 0.110 |
Why?
| | Erythrocytes | 1 | 2021 | 757 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 61 | 0.110 |
Why?
| | Up-Regulation | 2 | 2016 | 863 | 0.110 |
Why?
| | International Agencies | 1 | 2014 | 31 | 0.110 |
Why?
| | Gram-Positive Bacteria | 1 | 2014 | 48 | 0.110 |
Why?
| | Fructosamine | 1 | 2014 | 15 | 0.110 |
Why?
| | Video Recording | 2 | 2015 | 210 | 0.110 |
Why?
| | Health Records, Personal | 1 | 2014 | 27 | 0.110 |
Why?
| | Dairy Products | 1 | 2014 | 31 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2015 | 274 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 27 | 0.110 |
Why?
| | Carotid Artery Diseases | 3 | 2000 | 68 | 0.110 |
Why?
| | Societies, Scientific | 1 | 2014 | 51 | 0.110 |
Why?
| | Acetaminophen | 1 | 2017 | 263 | 0.110 |
Why?
| | Gram-Negative Bacteria | 1 | 2014 | 79 | 0.110 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2914 | 0.110 |
Why?
| | Bias | 1 | 2015 | 205 | 0.100 |
Why?
| | Renal Insufficiency | 1 | 2016 | 167 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 342 | 0.100 |
Why?
| | Eicosapentaenoic Acid | 1 | 2013 | 36 | 0.100 |
Why?
| | Cholesterol, Dietary | 1 | 2013 | 15 | 0.100 |
Why?
| | Hemodynamics | 1 | 2018 | 1116 | 0.100 |
Why?
| | Siblings | 3 | 2018 | 196 | 0.100 |
Why?
| | Eggs | 1 | 2013 | 25 | 0.100 |
Why?
| | Gene Expression | 3 | 2021 | 1514 | 0.100 |
Why?
| | Creatinine | 4 | 2018 | 492 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 179 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 324 | 0.100 |
Why?
| | Research Support as Topic | 1 | 2013 | 79 | 0.100 |
Why?
| | Heart Rate | 3 | 2010 | 843 | 0.090 |
Why?
| | Biological Specimen Banks | 1 | 2013 | 101 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2015 | 163 | 0.090 |
Why?
| | Hypoxia | 1 | 2020 | 1202 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2012 | 25 | 0.090 |
Why?
| | Mice | 11 | 2022 | 18471 | 0.090 |
Why?
| | Anesthesiology | 1 | 2015 | 171 | 0.090 |
Why?
| | Organizational Innovation | 1 | 2013 | 127 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2023 | 727 | 0.090 |
Why?
| | Chromosomes, Human, Pair 2 | 2 | 2009 | 28 | 0.090 |
Why?
| | History, 21st Century | 1 | 2013 | 223 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2022 | 854 | 0.090 |
Why?
| | Stomach | 1 | 2012 | 109 | 0.090 |
Why?
| | Sex Characteristics | 7 | 2015 | 786 | 0.090 |
Why?
| | CpG Islands | 2 | 2023 | 167 | 0.090 |
Why?
| | Epistasis, Genetic | 1 | 2012 | 66 | 0.090 |
Why?
| | Pilot Projects | 4 | 2023 | 1858 | 0.090 |
Why?
| | Interleukin-4 | 2 | 2005 | 213 | 0.090 |
Why?
| | Specimen Handling | 1 | 2013 | 185 | 0.090 |
Why?
| | History, 20th Century | 1 | 2013 | 328 | 0.090 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 103 | 0.090 |
Why?
| | Intestine, Small | 2 | 2005 | 166 | 0.090 |
Why?
| | Nuclear Family | 2 | 2009 | 52 | 0.090 |
Why?
| | Hyperinsulinism | 2 | 2010 | 114 | 0.090 |
Why?
| | Lymphocytes | 1 | 2014 | 395 | 0.090 |
Why?
| | Calcifediol | 1 | 2011 | 32 | 0.090 |
Why?
| | Primary Prevention | 1 | 2013 | 195 | 0.090 |
Why?
| | Intestines | 1 | 2014 | 358 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 907 | 0.090 |
Why?
| | Pedigree | 4 | 2017 | 513 | 0.090 |
Why?
| | Patient Selection | 3 | 2011 | 696 | 0.090 |
Why?
| | Gliadin | 2 | 2009 | 13 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1266 | 0.090 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 194 | 0.080 |
Why?
| | Vaccines | 1 | 2016 | 387 | 0.080 |
Why?
| | HLA-B Antigens | 1 | 2011 | 57 | 0.080 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2011 | 24 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2011 | 157 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2012 | 447 | 0.080 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.080 |
Why?
| | Thyroglobulin | 3 | 2025 | 30 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2032 | 0.080 |
Why?
| | Viruses | 1 | 2013 | 165 | 0.080 |
Why?
| | Vascular Diseases | 2 | 2013 | 251 | 0.080 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.080 |
Why?
| | Food, Fortified | 1 | 2010 | 42 | 0.080 |
Why?
| | Linkage Disequilibrium | 4 | 2015 | 249 | 0.080 |
Why?
| | Weight Gain | 2 | 2011 | 559 | 0.080 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 209 | 0.080 |
Why?
| | Milk, Human | 3 | 2018 | 171 | 0.080 |
Why?
| | Decision Support Techniques | 2 | 2013 | 447 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2012 | 396 | 0.080 |
Why?
| | Myocardial Infarction | 2 | 1994 | 1084 | 0.080 |
Why?
| | Nutrition Assessment | 2 | 2015 | 92 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2010 | 158 | 0.080 |
Why?
| | Lymphocyte Activation | 1 | 2014 | 1143 | 0.080 |
Why?
| | Microbiota | 2 | 2014 | 782 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 580 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.080 |
Why?
| | Family | 5 | 2018 | 692 | 0.080 |
Why?
| | Socioeconomic Factors | 5 | 2017 | 1327 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2002 | 1183 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1739 | 0.080 |
Why?
| | RNA | 1 | 2016 | 941 | 0.070 |
Why?
| | Quality Control | 3 | 2013 | 165 | 0.070 |
Why?
| | Waist-Hip Ratio | 2 | 2009 | 37 | 0.070 |
Why?
| | Pancreas | 2 | 2023 | 335 | 0.070 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 364 | 0.070 |
Why?
| | Bifidobacterium | 2 | 2018 | 21 | 0.070 |
Why?
| | Homeostasis | 2 | 2010 | 639 | 0.070 |
Why?
| | Sequence Analysis, DNA | 3 | 2011 | 828 | 0.070 |
Why?
| | Antigens, Viral | 2 | 2021 | 183 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 102 | 0.070 |
Why?
| | Algorithms | 3 | 2026 | 1844 | 0.070 |
Why?
| | Glycemic Index | 1 | 2008 | 27 | 0.070 |
Why?
| | Isoenzymes | 2 | 2006 | 300 | 0.070 |
Why?
| | Spleen | 1 | 2010 | 517 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2016 | 626 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2012 | 791 | 0.070 |
Why?
| | Laboratories | 1 | 2009 | 111 | 0.070 |
Why?
| | DEAD-box RNA Helicases | 1 | 2008 | 90 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 377 | 0.070 |
Why?
| | Telomere | 3 | 2022 | 286 | 0.070 |
Why?
| | Disease Outbreaks | 2 | 1991 | 423 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 294 | 0.070 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.060 |
Why?
| | Lipoproteins, LDL | 2 | 2008 | 114 | 0.060 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 24 | 0.060 |
Why?
| | Clinical Competence | 1 | 2015 | 1232 | 0.060 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 99 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1902 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 575 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2009 | 240 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 156 | 0.060 |
Why?
| | Drug Utilization | 2 | 2017 | 163 | 0.060 |
Why?
| | Physicians | 1 | 2015 | 933 | 0.060 |
Why?
| | Datasets as Topic | 2 | 2018 | 126 | 0.060 |
Why?
| | Wheat Hypersensitivity | 1 | 2006 | 4 | 0.060 |
Why?
| | Insulin Infusion Systems | 2 | 2017 | 479 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2014 | 630 | 0.060 |
Why?
| | Population Surveillance | 3 | 2020 | 491 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 29 | 0.060 |
Why?
| | Antibody Specificity | 4 | 2011 | 185 | 0.060 |
Why?
| | Apolipoprotein C-III | 1 | 2006 | 11 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 564 | 0.060 |
Why?
| | Epitope Mapping | 2 | 2024 | 65 | 0.060 |
Why?
| | Birth Order | 2 | 2004 | 13 | 0.060 |
Why?
| | Adenovirus Infections, Human | 1 | 2005 | 16 | 0.060 |
Why?
| | Paired Box Transcription Factors | 1 | 2005 | 43 | 0.060 |
Why?
| | Carrier State | 1 | 2006 | 79 | 0.060 |
Why?
| | Adenoviruses, Human | 1 | 2005 | 27 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 444 | 0.060 |
Why?
| | Receptors, Interleukin-4 | 1 | 2005 | 16 | 0.060 |
Why?
| | Metagenomics | 2 | 2019 | 180 | 0.060 |
Why?
| | Chronic Disease | 4 | 2017 | 1826 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 432 | 0.060 |
Why?
| | Codon, Terminator | 1 | 2005 | 25 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 78 | 0.060 |
Why?
| | Chromatography, Liquid | 3 | 2012 | 454 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2026 | 96 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 304 | 0.060 |
Why?
| | Codon, Nonsense | 1 | 2005 | 44 | 0.060 |
Why?
| | Protective Factors | 2 | 2015 | 102 | 0.060 |
Why?
| | Capsid Proteins | 1 | 2005 | 96 | 0.060 |
Why?
| | Fathers | 1 | 2005 | 51 | 0.050 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.050 |
Why?
| | Interleukin-13 | 1 | 2005 | 150 | 0.050 |
Why?
| | Norway | 2 | 2019 | 46 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 110 | 0.050 |
Why?
| | Research Design | 3 | 2019 | 1122 | 0.050 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 56 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 562 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4578 | 0.050 |
Why?
| | Nutritional Status | 1 | 2007 | 351 | 0.050 |
Why?
| | Survivors | 1 | 2008 | 513 | 0.050 |
Why?
| | Cattle | 3 | 2017 | 1005 | 0.050 |
Why?
| | Anthropometry | 1 | 2004 | 204 | 0.050 |
Why?
| | Pennsylvania | 2 | 2018 | 136 | 0.050 |
Why?
| | Waist Circumference | 2 | 2015 | 141 | 0.050 |
Why?
| | Postmenopause | 3 | 2020 | 391 | 0.050 |
Why?
| | Metagenome | 1 | 2025 | 148 | 0.050 |
Why?
| | Insulin, Isophane | 1 | 2003 | 22 | 0.050 |
Why?
| | Registries | 7 | 2019 | 2248 | 0.050 |
Why?
| | Transcriptome | 2 | 2023 | 1049 | 0.050 |
Why?
| | DNA | 2 | 2011 | 1430 | 0.050 |
Why?
| | Cross-Cultural Comparison | 2 | 2015 | 82 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2004 | 331 | 0.050 |
Why?
| | International Cooperation | 3 | 2016 | 197 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 89 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 335 | 0.050 |
Why?
| | Iron, Dietary | 1 | 2023 | 23 | 0.050 |
Why?
| | Aspartic Acid | 1 | 2023 | 88 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2005 | 275 | 0.050 |
Why?
| | Computer Simulation | 2 | 2026 | 1033 | 0.050 |
Why?
| | Creatine | 1 | 2023 | 63 | 0.050 |
Why?
| | Glycomics | 1 | 2022 | 7 | 0.050 |
Why?
| | Biomedical Research | 1 | 2009 | 714 | 0.050 |
Why?
| | Markov Chains | 2 | 2020 | 125 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 127 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 353 | 0.050 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2019 | 16 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2006 | 459 | 0.050 |
Why?
| | Electrocardiography | 2 | 2010 | 636 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 3124 | 0.050 |
Why?
| | Candida | 1 | 2022 | 44 | 0.050 |
Why?
| | Choline | 1 | 2023 | 135 | 0.050 |
Why?
| | HLA-B15 Antigen | 2 | 2012 | 11 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 478 | 0.050 |
Why?
| | Insulins | 1 | 2022 | 39 | 0.040 |
Why?
| | Prenatal Care | 1 | 2004 | 306 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2005 | 524 | 0.040 |
Why?
| | Electrochemistry | 1 | 2021 | 73 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 397 | 0.040 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 20 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 44 | 0.040 |
Why?
| | China | 1 | 2021 | 225 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 31 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 53 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 103 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2025 | 16805 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 114 | 0.040 |
Why?
| | Perception | 1 | 2023 | 379 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2026 | 889 | 0.040 |
Why?
| | Fungi | 1 | 2022 | 161 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.040 |
Why?
| | Isotopes | 1 | 2020 | 34 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 779 | 0.040 |
Why?
| | Dehydroascorbic Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Neutrophils | 1 | 2026 | 1146 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 155 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2006 | 696 | 0.040 |
Why?
| | Antibody Diversity | 1 | 2019 | 16 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 13 | 0.040 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2020 | 39 | 0.040 |
Why?
| | Models, Statistical | 3 | 2015 | 680 | 0.040 |
Why?
| | Glucose Transporter Type 2 | 1 | 2019 | 16 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 170 | 0.040 |
Why?
| | Growth Charts | 1 | 2020 | 20 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 133 | 0.040 |
Why?
| | Viral Proteins | 2 | 2006 | 365 | 0.040 |
Why?
| | Haemophilus influenzae type b | 1 | 1999 | 12 | 0.040 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1999 | 27 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 63 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2020 | 60 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 76 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1999 | 29 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 600 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 206 | 0.040 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2019 | 47 | 0.040 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 1999 | 27 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 181 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 288 | 0.040 |
Why?
| | Proline | 1 | 2020 | 82 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 122 | 0.040 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2019 | 26 | 0.040 |
Why?
| | Hepatitis B Vaccines | 1 | 1999 | 42 | 0.040 |
Why?
| | Efficiency | 1 | 2020 | 103 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 131 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 163 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 318 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 191 | 0.040 |
Why?
| | Depression | 1 | 2009 | 1525 | 0.040 |
Why?
| | Texas | 2 | 2014 | 278 | 0.040 |
Why?
| | Maternal Behavior | 1 | 1999 | 82 | 0.040 |
Why?
| | Receptor, Insulin | 1 | 1999 | 94 | 0.040 |
Why?
| | Alanine | 1 | 2020 | 168 | 0.040 |
Why?
| | Proteobacteria | 1 | 2018 | 16 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 431 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 593 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 578 | 0.040 |
Why?
| | Adenoviridae | 1 | 2019 | 203 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 48 | 0.040 |
Why?
| | Pets | 1 | 2018 | 26 | 0.040 |
Why?
| | Down-Regulation | 1 | 2021 | 641 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 348 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 322 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2018 | 18 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2018 | 79 | 0.030 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.030 |
Why?
| | Fatty Acids, Volatile | 1 | 2018 | 60 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 252 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2020 | 192 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 41 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2000 | 247 | 0.030 |
Why?
| | Employment | 1 | 2020 | 180 | 0.030 |
Why?
| | Postpartum Period | 1 | 2021 | 360 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 441 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 168 | 0.030 |
Why?
| | Apolipoprotein A-I | 1 | 1997 | 30 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 251 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2930 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 135 | 0.030 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 46 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 142 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2017 | 37 | 0.030 |
Why?
| | Bicarbonates | 1 | 2017 | 45 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2018 | 366 | 0.030 |
Why?
| | Canada | 1 | 2018 | 425 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 467 | 0.030 |
Why?
| | Vitamin E | 1 | 1997 | 117 | 0.030 |
Why?
| | Biopsy, Needle | 2 | 2011 | 184 | 0.030 |
Why?
| | Galactosamine | 1 | 2016 | 3 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 48 | 0.030 |
Why?
| | Lipoprotein(a) | 1 | 1997 | 66 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2015 | 1072 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 530 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 174 | 0.030 |
Why?
| | Acetylglucosamine | 1 | 2016 | 13 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 364 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 325 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 332 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 37 | 0.030 |
Why?
| | Africa | 2 | 1996 | 113 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 639 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2017 | 82 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2018 | 509 | 0.030 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 13 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1104 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2017 | 157 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 315 | 0.030 |
Why?
| | Genetic Background | 1 | 2015 | 16 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 315 | 0.030 |
Why?
| | Anemia, Sickle Cell | 1 | 2000 | 309 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 79 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1270 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 499 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 769 | 0.030 |
Why?
| | Analysis of Variance | 3 | 2010 | 1309 | 0.030 |
Why?
| | Georgia | 1 | 2015 | 86 | 0.030 |
Why?
| | DNA Primers | 1 | 1996 | 517 | 0.030 |
Why?
| | Genes | 1 | 1995 | 226 | 0.030 |
Why?
| | Radioligand Assay | 2 | 2009 | 37 | 0.030 |
Why?
| | Florida | 1 | 2015 | 115 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 436 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 315 | 0.030 |
Why?
| | Quality of Life | 2 | 2024 | 3146 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 752 | 0.030 |
Why?
| | Washington | 1 | 2015 | 161 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 239 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 681 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 334 | 0.030 |
Why?
| | Airway Management | 1 | 2015 | 81 | 0.030 |
Why?
| | Insulin, Long-Acting | 2 | 2005 | 65 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 141 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 392 | 0.030 |
Why?
| | Tunica Intima | 3 | 2000 | 76 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 140 | 0.030 |
Why?
| | Insulin Glargine | 2 | 2005 | 87 | 0.030 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.030 |
Why?
| | Hospitalization | 1 | 2004 | 2346 | 0.030 |
Why?
| | Epidemiologic Factors | 1 | 2013 | 10 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2013 | 50 | 0.030 |
Why?
| | Family Characteristics | 1 | 2015 | 199 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 60 | 0.020 |
Why?
| | Base Sequence | 2 | 2011 | 2188 | 0.020 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2012 | 6 | 0.020 |
Why?
| | Asthma | 1 | 2025 | 1916 | 0.020 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2012 | 11 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2015 | 311 | 0.020 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2012 | 8 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 118 | 0.020 |
Why?
| | Niacinamide | 1 | 1993 | 86 | 0.020 |
Why?
| | S100 Proteins | 1 | 2012 | 36 | 0.020 |
Why?
| | Nurses | 1 | 2015 | 179 | 0.020 |
Why?
| | California | 2 | 2004 | 465 | 0.020 |
Why?
| | Vaccines, Inactivated | 1 | 2012 | 70 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2015 | 312 | 0.020 |
Why?
| | Biometry | 1 | 1993 | 68 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1638 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 153 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 152 | 0.020 |
Why?
| | Genome | 1 | 2014 | 304 | 0.020 |
Why?
| | Nerve Growth Factors | 1 | 2012 | 78 | 0.020 |
Why?
| | Aging | 3 | 2000 | 1972 | 0.020 |
Why?
| | Nitrates | 1 | 1992 | 99 | 0.020 |
Why?
| | Water Supply | 1 | 1992 | 88 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2011 | 14 | 0.020 |
Why?
| | Observation | 1 | 2011 | 51 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2011 | 6 | 0.020 |
Why?
| | Potassium Channels | 1 | 2012 | 145 | 0.020 |
Why?
| | Adenosine Triphosphatases | 1 | 2012 | 161 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 1998 | 948 | 0.020 |
Why?
| | Phylogeny | 2 | 2006 | 1012 | 0.020 |
Why?
| | Ubiquitins | 1 | 2011 | 34 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 50 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2014 | 377 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1503 | 0.020 |
Why?
| | Insulinoma | 1 | 2011 | 28 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 138 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 331 | 0.020 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2011 | 24 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 865 | 0.020 |
Why?
| | Causality | 1 | 1991 | 126 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2007 | 706 | 0.020 |
Why?
| | Leptin | 1 | 2012 | 244 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2015 | 568 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2909 | 0.020 |
Why?
| | Endothelium, Vascular | 2 | 2008 | 966 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 13 | 0.020 |
Why?
| | Biostatistics | 1 | 2009 | 19 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2009 | 30 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 30 | 0.020 |
Why?
| | Fetal Weight | 1 | 2009 | 55 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 259 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 153 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 408 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 101 | 0.020 |
Why?
| | Pancreatic Polypeptide | 1 | 1989 | 4 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8154 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 517 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 838 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1418 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2008 | 30 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 2009 | 101 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 44 | 0.020 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 20 | 0.020 |
Why?
| | Tunica Media | 2 | 2000 | 36 | 0.020 |
Why?
| | Protein Precursors | 1 | 2009 | 136 | 0.020 |
Why?
| | Survival Rate | 2 | 2006 | 2036 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 184 | 0.020 |
Why?
| | Telecommunications | 1 | 1988 | 22 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2008 | 32 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2008 | 36 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 992 | 0.020 |
Why?
| | Pacific Islands | 1 | 1988 | 3 | 0.020 |
Why?
| | Solanum tuberosum | 1 | 2008 | 8 | 0.020 |
Why?
| | Outpatients | 1 | 1992 | 431 | 0.020 |
Why?
| | Glucagon | 1 | 1989 | 106 | 0.020 |
Why?
| | Probability | 1 | 1989 | 306 | 0.020 |
Why?
| | Americas | 1 | 1988 | 26 | 0.020 |
Why?
| | Asia | 1 | 1988 | 68 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 97 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 2009 | 121 | 0.020 |
Why?
| | Survival | 1 | 2007 | 38 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 19 | 0.020 |
Why?
| | Carotenoids | 1 | 2007 | 47 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 170 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1734 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 188 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 46 | 0.020 |
Why?
| | 5' Untranslated Regions | 1 | 2006 | 60 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2006 | 75 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2006 | 58 | 0.020 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2006 | 63 | 0.020 |
Why?
| | Serotyping | 1 | 2005 | 32 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1524 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2006 | 362 | 0.010 |
Why?
| | Self Care | 1 | 2009 | 399 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2013 | 2859 | 0.010 |
Why?
| | Species Specificity | 1 | 2006 | 575 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 29 | 0.010 |
Why?
| | Cause of Death | 2 | 2002 | 461 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2005 | 138 | 0.010 |
Why?
| | Puerto Rico | 1 | 2004 | 54 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 371 | 0.010 |
Why?
| | Ultrasonography | 2 | 2000 | 766 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 180 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 646 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2004 | 11501 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 126 | 0.010 |
Why?
| | Regeneration | 1 | 2005 | 197 | 0.010 |
Why?
| | Genome, Viral | 1 | 2005 | 222 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2003 | 91 | 0.010 |
Why?
| | Insulin Lispro | 1 | 2003 | 42 | 0.010 |
Why?
| | DNA, Viral | 1 | 2005 | 361 | 0.010 |
Why?
| | Mutation | 1 | 2015 | 4120 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 310 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2008 | 2185 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2005 | 270 | 0.010 |
Why?
| | Duodenum | 1 | 2003 | 78 | 0.010 |
Why?
| | Health | 1 | 2003 | 82 | 0.010 |
Why?
| | Income | 1 | 2003 | 197 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 54 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 101 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 221 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4172 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 85 | 0.010 |
Why?
| | Carotid Artery, Internal | 1 | 2000 | 44 | 0.010 |
Why?
| | Carotid Artery, Common | 1 | 2000 | 32 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 278 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 1985 | 516 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 1999 | 5 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 999 | 0.010 |
Why?
| | Genetic Counseling | 1 | 1999 | 82 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1999 | 107 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5256 | 0.010 |
Why?
| | Twins, Monozygotic | 1 | 1999 | 132 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1998 | 169 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 276 | 0.010 |
Why?
| | Demography | 1 | 1998 | 289 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1171 | 0.010 |
Why?
| | Quantitative Trait, Heritable | 1 | 1997 | 117 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2630 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 1998 | 347 | 0.010 |
Why?
| | Bacterial Infections | 1 | 1998 | 247 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1998 | 422 | 0.010 |
Why?
| | Mexico | 1 | 1996 | 232 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 2533 | 0.010 |
Why?
| | Mental Disorders | 1 | 2002 | 1129 | 0.010 |
Why?
| | Baltic States | 1 | 1992 | 1 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1998 | 942 | 0.010 |
Why?
| | Rats | 1 | 2000 | 5626 | 0.010 |
Why?
| | Geography | 1 | 1992 | 202 | 0.010 |
Why?
| | Software | 1 | 1997 | 692 | 0.010 |
Why?
| | Cohort Effect | 1 | 1990 | 4 | 0.010 |
Why?
| | Periodicity | 1 | 1990 | 59 | 0.000 |
Why?
| | Space-Time Clustering | 1 | 1989 | 3 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1989 | 22 | 0.000 |
Why?
| | Coxsackievirus Infections | 1 | 1987 | 14 | 0.000 |
Why?
| | Rubella | 1 | 1987 | 22 | 0.000 |
Why?
| | Mortality | 1 | 1989 | 362 | 0.000 |
Why?
| | Neoplasms | 1 | 1989 | 2914 | 0.000 |
Why?
|
|
Rewers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|